Xinghua (Victor) PAN
Associate Research Scientist
Dr. Xinghua (Victor) Pan earned his Ph.D. degree with Dr. CC Tan and Z Geng from the Institute of Genetics, Fudan University School of Life Science, Shanghai, China. His thesis research was on the genetic associations between HLA and SLE and myasthenia gravis. He also obtained his M.D. degree (equivalent) from the Southern Medical University (previously called First Military Medical University), Guangzhou, China. Then he got his postdoctoral training at the National Key Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) with Dr. Min WU, identifying a candidate tumor suppressor gene with a grant support from the China Postdoctoral Science Foundation. Beginning in December 1994, he served as Associate Professor in Genetics in the Department of Biology, Second Military Medical University, Shanghai, China, where he earned a grant from the National Natural Science Foundation of China (NSFC), with which he established nm23 transgenic mouse and elucidated its effect on hepatocarcinoma. In addition, he studied EBV BHRF1 on nasopharyngeal carcinoma, reconstructed the phylogenetic tree for MHC genes. In 1997, Dr. Pan joined Dr. Sherman Weissman’s laboratory as a Postdoctoral Fellow in the Department of Genetics, Yale University School of Medicine, and developed an approach (GADAV) for unconditionally globally scanning of DNA mutations. From 2000 to 2004, he worked with Dr. Roger Lasken for Molecular Staging Inc. as a Research Scientist in Genomics Section and then Enzymology Leader, substantially contributed to the development of a kit for whole-genome-amplification (WGA), REPLIg, which is currently used world-wide and regarded as one of the best WGA technologies.
Dr. Pan’s main interest is functional genomics, focusing on the development and application of functional genomics technologies for analysis of single cells and low quantity of cells. These approaches include whole DNA pool amplification, whole mRNA transcriptome amplification, CpG methylation pattern scanning, DNase hypersensitive and resistant sites profiling, and telomere size analysis. Combining these technologies with second generation sequencing and microfluidic platform, and collaborating with other research teams, his group explores the genomic and epigenomic mechanism for reprogramming and transdifferentiation of human induced pluripotent stem cells (iPS), differentiation of embryo stem cells (ESCs) and adult stem cells (ASC, including hematopoietic stem cells, mesenchymal stem cells), molecular regulation underlying sensory neurons, embryo development and carcinogenesis and translational medicine.